Delivery Order SPE2DB22D2009-SPE2DB25FM0RK
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,248.36 to AmerisourceBergen Drug Corp for the supply of Mestinon 180 mg Timespan in quantities of 30 units. This firm fixed-price, competitively awarded contract was executed on August 4, 2025, with an ultimate completion date of August 5, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Mestinon is a pharmaceutical product used in the treatment of myasthenia gravis and related...
- The Defense Logistics Agency awarded a $5,900.40 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Mestinon 180 mg Timespan in quantities of 30 units. This is a non-set-aside, competitively awarded contract with an ultimate completion date of August 11, 2025. The place of performance is AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $5,667.30 by the Defense Logistics Agency's Medical Supply Chain on August 8, 2025, for the supply of Mestinon 180 mg Timespan in units of 30 tablets. The contract is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. Performance will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 11, 2025....
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of MESTINON 180 MG TIMESPAN UU 30S, a pharmaceutical product, with a ceiling value of $11,065.59 and a period of performance ending on May 29, 2025. The contract is a firm-fixed-price delivery order and is not a set-aside contract, indicating open competition. Amerisourcebergen Drug Corp is...
- This federal contract award is a Delivery Order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider based in Conshohocken, Pennsylvania. The contract is for the supply of MESTINON 180 MG TIMESPAN UU 30S, a prescription medication, with a ceiling value of $2,245.38. The contract is a Firm Fixed Price arrangement and is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $1,963.15 firm-fixed-price contract is for the supply of Mestinon 180 mg Timespan medication. This delivery order falls under a larger Indefinite Delivery Contract with the DLA Troop Support Medical valued up to $999,999,999 through December 2025, which provides a wide range of pharmaceutical and medical supplies to military treatment facilities and...
- This federal contract award is a $6,196.15 firm fixed-price delivery order from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of MESTINON 180 MG TIMESPAN UU 30S, a pharmaceutical product. The contract has an ultimate completion date of May 14, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which provides a...
- This is a delivery order federal contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of MESTINON 180 MG TIMESPAN UU 30S medication. The contract has a firm fixed price of $5,440.14 and a completion date of May 21, 2024. The contract is not designated as a set-aside. AmerisourceBergen Drug Corp holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
- This is a delivery order federal contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of MESTINON 180 MG TIMESPAN UU 30S, a prescription medication, with a ceiling value of $5,620.37. The contract is a firm fixed price arrangement with a performance period extending through June 16, 2025. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC)...
- This federal contract award, valued at $4,524.79, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4566357415 ! MESTINON 180 MG TIMESPAN UU 30S, a pharmaceutical product. The contract is a Delivery Order with a Firm Fixed Price pricing type, and has an ultimate completion date of November 7, 2024. It is not designated as a set-aside contract. Amerisourcebergen...
- SPE2DB22D2009Indefinite Delivery Contract
- SPE2DB22D2009-SPE2DB25FM0RKDelivery Order
The Defense Logistics Agency awarded a $3,998.11 delivery order to AmerisourceBergen Drug Corp for Mestinon 180 mg Timespan in quantities of 30 units. This is a firm fixed-price, competitively awarded contract with no set-aside designation, featuring an ultimate completion date of August 5, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform the work at its Corporate Office location in Conshohocken, PA 19428. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The parent IDC functions as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. The procurement of Mestinon, a medication used primarily for myasthenia gravis and other neuromuscular conditions, reflects the contractor's role in fulfilling critical pharmaceutical needs across the Defense Health Agency and military healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.0k | 8/4/25 |